Pulmonary Hypertension Treatment
Treatment of pulmonary hypertension must be tailored to the specific WHO group, with Group 1 PAH requiring aggressive upfront combination therapy targeting multiple pathophysiologic pathways, while Groups 2,3, and 5 focus on treating the underlying disease, and Group 4 CTEPH requires pulmonary endarterectomy as first-line therapy.
Initial Evaluation and Diagnosis
Right heart catheterization (RHC) is mandatory to confirm the diagnosis and guide treatment decisions in all suspected PAH cases (Group 1) and CTEPH (Group 4) 1. RHC must be performed in expert centers due to technical demands and potential complications 1. For Groups 2 and 3, RHC should be considered when organ transplantation is planned or when differential diagnosis assistance is needed 1.
Vasoreactivity testing is indicated only in IPAH, heritable PAH, and drug-induced PAH—not in other PAH subtypes or PH Groups 2-5 1. A positive response requires mean PAP reduction ≥10 mmHg to an absolute value ≤40 mmHg with stable or increased cardiac output, using inhaled nitric oxide or IV epoprostenol 1.
Group 1: Pulmonary Arterial Hypertension
Risk Stratification
Perform comprehensive risk assessment using WHO functional class, NT-proBNP levels, and 6-minute walk distance to categorize patients into low, intermediate, or high-risk groups 2. This stratification directly determines treatment intensity.
Treatment Algorithm
Low to Intermediate Risk:
- Initiate upfront dual combination therapy with a phosphodiesterase-5 inhibitor plus an endothelin receptor antagonist 2
- This represents a paradigm shift from sequential monotherapy and reflects current evidence supporting early aggressive treatment 3
High Risk:
- Consider initial triple combination therapy adding prostacyclin analogues to the dual oral regimen 2
- High-risk features include WHO FC IV, severely elevated NT-proBNP, and markedly reduced exercise capacity
Vasoreactive Patients:
- Only the small subset (<10%) with positive vasoreactivity testing should receive high-dose calcium channel blockers 1
- Oral or IV CCBs during acute testing are contraindicated 1
Emerging Therapies
Sotatercept, a novel agent targeting underlying vascular abnormalities, represents a shift toward disease modification rather than pure vasodilation 3, 4. Integration into treatment algorithms is evolving following recent approval.
Group 2: PH Due to Left Heart Disease
Treat the underlying left heart disease aggressively—this is the primary intervention 5. PAH-specific therapies are not recommended for routine use and may worsen outcomes by increasing pulmonary capillary pressures.
RHC is indicated only when transplantation is considered or when severe PH (PVR >5 Wood units) requires referral to specialized centers for potential study enrollment 1, 2.
Group 3: PH Due to Lung Disease and/or Hypoxia
Optimize treatment of the underlying lung disease and provide supplemental oxygen to correct hypoxemia 5. This is the cornerstone of management.
PAH-specific medications are not routinely recommended. Refer patients with severe PH (PVR >5 Wood units) to PH centers for consideration of clinical trials 2. Long-term oxygen therapy improves survival in hypoxemic patients.
Group 4: Chronic Thromboembolic Pulmonary Hypertension
Pulmonary endarterectomy (PEA) is the first-line treatment and should be performed in specialized CTEPH centers 2. This is potentially curative.
Treatment Pathway:
- Confirm diagnosis with RHC 1
- Evaluate surgical accessibility of thrombi
- Perform PEA in operable patients at expert centers
- For inoperable or residual/recurrent CTEPH:
- Medical therapy with riociguat or other PAH-targeted drugs
- Balloon pulmonary angioplasty (BPA) at specialized centers 2
All diagnostic and therapeutic decisions should occur within CTEPH centers with multidisciplinary teams 2.
Group 5: PH with Unclear/Multifactorial Mechanisms
Address all identifiable contributing factors 5. Treatment is highly individualized based on the specific underlying conditions (sarcoidosis, hematologic disorders, metabolic diseases, etc.).
Patients with severe PH (PVR >5 Wood units) warrant referral to PH centers for potential trial enrollment or off-label therapy consideration 2.
Critical Pitfalls to Avoid
- Never use PAH-specific therapies in Group 2 PH outside clinical trials—they may worsen pulmonary edema and outcomes
- Do not perform vasoreactivity testing in non-Group 1 patients—it provides no therapeutic guidance 1
- Avoid sequential monotherapy in newly diagnosed PAH—current evidence supports upfront combination therapy for better outcomes 2
- Do not manage CTEPH without surgical evaluation—missing operable disease denies patients potentially curative treatment
- Never prescribe CCBs without documented vasoreactivity—inappropriate use in non-responders can cause harm 1
Follow-Up Assessment
Reassess PAH patients every 3-6 months using the same risk stratification parameters. Escalate therapy if patients remain intermediate or high risk despite treatment 2. The goal is achieving and maintaining low-risk status across all parameters.